FDA halts Avandia trial enrollment
The U.S. Food and Drug Administration (FDA) notified GlaxoSmithKline that the post-marketing trial of Avandia (rosiglitazone) is on “partial clinical hold,” meaning no new patients can be enrolled…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.